Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2008-01-29
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S124000
Reexamination Certificate
active
10727168
ABSTRACT:
Compounds of formula (I), (Ia) and (Ib)useful as a medicament.
REFERENCES:
patent: 2503059 (1950-04-01), Miescher et al.
patent: 2599000 (1952-06-01), Kerwin et al.
patent: 3381009 (1968-04-01), Palazzo et al.
patent: 3511836 (1970-05-01), Hess
patent: 3527761 (1970-09-01), Archibald et al.
patent: 3997666 (1976-12-01), Witte et al.
patent: 4026894 (1977-05-01), Winn et al.
patent: 4188390 (1980-02-01), Campbell
patent: 4252721 (1981-02-01), Silvestrini et al.
patent: 4315007 (1982-02-01), Manoury
patent: 4703063 (1987-10-01), Imai et al.
patent: 5077290 (1991-12-01), Fisher et al.
patent: 5258513 (1993-11-01), Van Keulen et al.
patent: 5348956 (1994-09-01), Van Keulen et al.
patent: 5576322 (1996-11-01), Takase et al.
patent: 5698560 (1997-12-01), Onoda et al.
patent: 6037346 (2000-03-01), Doherty et al.
patent: 6297382 (2001-10-01), Scott
patent: 0463756 (1992-01-01), None
patent: 0526004 (1992-07-01), None
patent: 0995750 (2000-04-01), None
patent: 0995751 (2000-04-01), None
patent: 1092718 (2001-04-01), None
patent: 1092719 (2001-04-01), None
patent: 851311 (1960-10-01), None
patent: 851311 (1960-10-01), None
patent: 2095353 (1997-10-01), None
patent: 1154907 (1996-09-01), None
patent: WO 9218489 (1962-10-01), None
patent: WO 9111172 (1991-08-01), None
patent: WO92/18489 (1992-10-01), None
patent: WO 9306104 (1993-04-01), None
patent: WO 9307149 (1993-04-01), None
patent: WO 9312095 (1993-06-01), None
patent: WO 9400453 (1994-01-01), None
patent: WO 9402518 (1994-02-01), None
patent: WO 9405661 (1994-03-01), None
patent: WO 9519978 (1995-07-01), None
patent: WO 9621656 (1996-07-01), None
patent: WO 9849166 (1998-11-01), None
patent: WO 9855148 (1998-12-01), None
patent: WO 9902159 (1999-01-01), None
patent: WO 9924433 (1999-05-01), None
patent: WO 9930697 (1999-06-01), None
patent: WO 9932475 (1999-07-01), None
patent: WO 9954333 (1999-10-01), None
patent: WO 9954358 (1999-10-01), None
patent: WO 9955679 (1999-11-01), None
patent: WO 9964002 (1999-12-01), None
patent: WO 9964008 (1999-12-01), None
patent: WO 0002550 (2000-01-01), None
patent: WO 0012075 (2000-03-01), None
patent: WO 0024745 (2000-05-01), None
patent: WO 0028993 (2000-05-01), None
patent: WO 0033825 (2000-06-01), None
patent: WO 0058361 (2000-10-01), None
patent: WO 0074679 (2000-12-01), None
patent: WO 0105401 (2001-01-01), None
patent: WO 0113112 (2001-02-01), None
patent: WO 0114879 (2001-03-01), None
patent: WO 0127112 (2001-04-01), None
patent: WO 0127113 (2001-04-01), None
Perrone, et al. Oxygen Derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 1992, 35, pp. 3045-3049.
Berman, et al., “Femal Sexual Dysfunction: Incidence, Pahtophysiology, Evaluation, and Treatment Options”,Urology54, pp. 385-391 (1999).
Melman, et al., “The Epidemiology and Pathophysiology of Erectile Dysfunction”,The Journal of Urology, 161, pp. 5-11 (1999).
Gonzalez, et al., “[3H]7-OH-DPAT is Capable of Labeling Dopamine D2as well as D3Receptors”,European Journal of Pharmacology272, pp. R1-R3 (1995).
Ballard, et al., “Effects of Sildenafil on the Relaxation of Human Corpus Cavenosum Tissue in Vitro and on the Activities of cyclic Nucleotide Phosphodiesterase Isozymes”,The Journal of Urology159(6), pp. 2164-2171 (1998).
Rotella, et al., “N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction”,J. Med. Chem., 43, pp. 1257-1263 (2000).
Berge, et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Sciences66(1), pp. 1-19 (1977).
Taub, et al., “Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavemosum”,Urology42(6), pp. 698-704 (1993).
Leiblum, “Definition and Classification of Female Secual Disorders”,International Journal of Impotence Research10(Suppl. 2), pp. S104-S106 (1998).
Goldstein, et al., “Vasculogenic Female Sexual Dysfunction: Vaginal Engorgement and Clitoral Erectile Insufficiency Syndromes”,International Journal of Impotence Research10(Suppl. 2), pp. S84-S90 (1998).
Park, et al., “Vasculogenic Female Sexual Dysfunction: The Hemodynamic Basis for Vaginal Engorgement Insufficiency and Clitoral Erectile Insufficiency”,International Journal of Impotence Research9, pp. 27-37 (1997).
Levin, “VIP Vagina, Clitoral and Periurethral Glans—an Update on Human Female Genital Arousal”,Exp. Clin. Endocrinol, 98(2), pp. 61-69 (1991).
Lerner, et al., “A Review of Erectile Dysfunction: New Insights and More Questions”,The Journal of Urology149, pp. 1246-1255 (1993).
Feldman, et al., “Impotence and its Medical and Psychosocial Correlates: Resulst of the Massachusetts Male Aging Study”,The Journal of Urology151, pp. 54-61 (1994).
Naylor, “Endogenous Neurotransmitters Mediating Penile Erection”,British Journal of Urology81, pp. 424-431 (1998).
Carrier, et al., “Erectile Dysfunction”,Clinical Andrology23(4), pp. 773-782 (1994).
Allerton Charlotte Moira Norfor
Baxter Andrew Douglas
Cook Andrew Simon
Hepworth David
Wong Stephen Kwok-Fung
Pfizer Inc.
Polster, II Philip B.
Saeed Kamal A.
LandOfFree
Morpholine dopamine agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morpholine dopamine agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholine dopamine agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926145